Literature DB >> 12796837

Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family.

Alexander Lossos1, Avinoam Reches, Aya Gal, Joel P Newman, Dov Soffer, John Moshe Gomori, Moshe Boher, Dana Ekstein, Iftah Biran, Zeev Meiner, Oded Abramsky, Hanna Rosenmann.   

Abstract

BACKGROUND: Frontotemporal dementia with parkinsonism linked to chromosome 17q21-22 (FTDP-17) is an autosomal dominant tauopathy manifested by a variable combination of personality changes, cognitive decline and hypokinetic-rigid movement disorder. Significant clinical and pathological heterogeneity of FTDP-17 is related in part to more than 20 different pathogenic mutations identified in the tau gene. Among others, the P301S mutation has been previously reported in three families of European and one of Japanese origin presenting with different clinical phenotypes.
OBJECTIVES: To report a three-generation family of Jewish-Algerian origin with FTDP-17 due to the P301S tau mutation.
METHODS: Clinical, neuropsychological and neuroimaging evaluation of 3 patients, tau genotyping, and pathological study of the proband.
RESULTS: The 3 affected family members had a fairly stereotyped clinical course with early personality changes from their late 30s followed within a period of 1-2 years by a progressive cognitive and motor deterioration eventually leading to a state of akinetic mutism or death 3-5 years after the initial symptoms. The main clinical manifestations included severe dementia and hypokinetic-rigid movement disorder associated with supranuclear gaze impairment, pyramidal signs and frontal release signs. Brain imaging disclosed a variable degree of frontotemporal atrophy, ventriculomegaly and regional cerebral hypoperfusion or glucose hypometabolism. Frontal lobe biopsy in the proband revealed weak tau immunoreactivity in a few cortical neurons, in rare neurites and in some glial cells with no neurofibrillary tangles. Molecular DNA analysis identified a P301S mutation in exon 10 of the tau gene.
CONCLUSIONS: The observed clinical features further expand the reported P301S phenotype and confirm a more aggressive course of the disease than in the other known tau mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796837     DOI: 10.1007/s00415-003-1074-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: an example of phenotype variability.

Authors:  W Casseron; J P Azulay; E Guedj; J L Gastaut; J Pouget
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 3.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

4.  Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301L MAPT mutation: dysexecutive, aphasic, apraxic or spatial phenomenon?

Authors:  Emilia J Sitek; Ewa Narozanska; Anna Barczak; Barbara Jasinska-Myga; Michał Harciarek; Małgorzata Chodakowska-Zebrowska; Małgorzata Kubiak; Dariusz Wieczorek; Seweryna Konieczna; Rosa Rademakers; Matt Baker; Mariusz Berdynski; Bogna Brockhuis; Maria Barcikowska; Cezary Zekanowski; Kenneth M Heilman; Zbigniew K Wszolek; Jarosław Slawek
Journal:  Neurocase       Date:  2012-11-05       Impact factor: 0.881

5.  Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers.

Authors:  Kacie D Deters; Shannon L Risacher; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Gary D Hutchins; Karmen K Yoder; Jill R Murrell; Salvatore Spina; Francine Epperson; Sujuan Gao; Andrew J Saykin; Bernardino Ghetti
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

6.  Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice.

Authors:  Termpanit Chalermpalanupap; Jason P Schroeder; Jacki M Rorabaugh; L Cameron Liles; James J Lah; Allan I Levey; David Weinshenker
Journal:  J Neurosci       Date:  2017-11-13       Impact factor: 6.167

Review 7.  Parkinsonism, movement disorders and genetics in frontotemporal dementia.

Authors:  José Fidel Baizabal-Carvallo; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2016-02-19       Impact factor: 42.937

8.  Clinical and genetic features of families with frontotemporal dementia and parkinsonism linked to chromosome 17 with a P301S tau mutation.

Authors:  Y Baba; M C Baker; I Le Ber; A Brice; L Maeck; J Kohlhase; M Yasuda; G Stoppe; O Bugiani; A D Sperfeld; Y Tsuboi; R J Uitti; M J Farrer; B Ghetti; M L Hutton; Z K Wszolek
Journal:  J Neural Transm (Vienna)       Date:  2007-02-23       Impact factor: 3.575

9.  Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia Starkova; Noel Y Calingasan; Lichuan Yang; Davide Tampellini; Anatoly A Starkov; Robin B Chan; Gilbert Di Paolo; Aurora Pujol; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

10.  Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases.

Authors:  Tarun V Kamath; Naomi Klickstein; Caitlin Commins; Analiese R Fernandes; Derek H Oakley; Matthew P Frosch; Bradley T Hyman; Simon Dujardin
Journal:  Brain Commun       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.